Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 10:10:967311.
doi: 10.3389/fpubh.2022.967311. eCollection 2022.

Expert consensus statement on therapeutic drug monitoring and individualization of linezolid

Bin Lin  1   2 , Yangmin Hu  3 , Ping Xu  4 , Tao Xu  4 , Chunyan Chen  4 , Le He  5 , Mi Zhou  6 , Zhangzhang Chen  7 , Chunhong Zhang  8 , Xuben Yu  8 , Luo Fang  9 , Junfeng Zhu  9 , Yanlan Ji  10 , Qun Lin  11 , Hengbin Cao  12 , Youqin Dai  13 , Xiaoyan Lu  13 , Changcheng Shi  14 , Li Li  15 , Changjiang Wang  16 , Xumei Li  16 , Qiongyan Fang  17 , Jing Miao  18 , Zhengyi Zhu  18 , Guangyong Lin  19 , Haichao Zhan  20 , Shiwen Lv  20 , Yalan Zhu  20 , Xinjun Cai  21 , Yin Ying  22 , Meng Chen  23 , Qiong Xu  24 , Yiwen Zhang  25 , Yubin Xu  26 , Pea Federico  27   28 , Saiping Jiang  29 , Haibin Dai  2   3
Affiliations

Expert consensus statement on therapeutic drug monitoring and individualization of linezolid

Bin Lin et al. Front Public Health. .

Abstract

Linezolid is an oxazolidinone antibacterial drug, and its therapeutic drug monitoring and individualized treatment have been challenged since its approval. With the in-depth clinical research of linezolid, we have changed our attitude toward its therapeutic drug monitoring and our view of individualized treatment. On the basis of summarizing the existing clinical studies, and based on the practical experience of each expert in their respective professional fields, we have formed this expert consensus. Our team of specialists is a multidisciplinary team that includes pharmacotherapists, clinical pharmacology specialists, critical care medicine specialists, respiratory specialists, infectious disease specialists, emergency medicine specialists and more. We are committed to the safe and effective use of linezolid in patients in need, and the promotion of its therapeutic drug monitoring.

Keywords: expert consensus; individualization; linezolid; pharmacotherapy; therapeutic drug monitoring.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents. (2004) 23:113–9. 10.1016/j.ijantimicag.2003.11.003 - DOI - PubMed
    1. Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother. (2003) 51:ii9–16. 10.1093/jac/dkg249 - DOI - PubMed
    1. Wen S, Zhang T, Yu X, Dong W, Lan T, Fan J, et al. . Bone penetration of linezolid in osteoarticular tuberculosis patients of China. Int J Infect Dis. (2021) 103:364–9. 10.1016/j.ijid.2020.11.203 - DOI - PubMed
    1. Li Y, Huang H, Dong W, Lan T, Fan J, Wen S, et al. . Penetration of linezolid into bone tissue 24 h after administration in patients with multidrug-resistant spinal tuberculosis. PLoS ONE. (2019) 14:e0223391. 10.1371/journal.pone.0223391 - DOI - PMC - PubMed
    1. Li Y, Dong W, Lan T, Fan J, Qin S, Guo A. Distribution of linezolid in tuberculosis lesions in patients with spinal multidrug-resistant tuberculosis. Antimicrob Agents Chemother. (2020) 64:e00450–20. 10.1128/AAC.00450-20 - DOI - PMC - PubMed

Publication types

LinkOut - more resources